Evidence item

Cancer Network independently reports the same testing-cohort performance figures for the PANXEON composite. DATASET_RESULT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group 95aaa2eb · created seq 14184

Source: PANXEON Liquid Biopsy Demonstrates Potential for Detecting Early Pancreatic Cancer · locator {} · excerpt hash sha256:6dccd5e5492529aa80efe44728e5129884ad34f33bcddb685de0be7b3e50457b

When combined with CA19-9 into the PANXEON composite score, sensitivity for stage I to II PDAC increased to 86.8%, with false-positive rates of 3.2% in low-risk controls and 15.6% in high-risk controls in the testing cohort.